Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Anti-CD30 CAR-T Cell Injection
- Development stage
- Unknown
- Lead developer
- Zhejiang University
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Anti-CD30 CAR-T Cell Injection is an autologous chimeric antigen receptor (CAR) T-cell therapy developed by Zhejiang University for the treatment of relapsed or refractory CD30-positive lymphomas. The therapy involves genetically engineering a patient's own T cells to express a CAR that specifically targets the CD30 antigen (also known as TNFRSF8), a member of the tumor necrosis factor receptor superfamily expressed on the surface of various malignant lymphoid cells, including Hodgkin lymphoma and certain non-Hodgkin lymphomas. Following lymphodepletion chemotherapy with fludarabine and cyclophosphamide, the engineered T cells are intravenously administered to the patient. Once in the body, these CAR-T cells recognize and bind to CD30-expressing tumor cells, leading to T-cell activation, expansion, and targeted cytotoxicity. It is currently being evaluated in Phase 1 clinical trials for a variety of CD30-positive hematologic malignancies.
- Other names
- Anti CD30 CAR-T CellsAnti-CD30 CAR-T Cell InjectionAnti-CD-30 CAR-T Cell InjectionAnti-CD 30 CAR-T Cell InjectionAnti CD30 CAR T Cells Injection
02
Targets
CD30 (CD30 antigen)
Beyond the preview
Go deeper on Anti-CD30 CAR-T Cell Injection.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Anti-CD30 CAR-T Cell Injection.